GlassScriptPhysician profile
Reshelle Pena
NPI 1194017111
$1,446.86
in general payments reported to CMS, 2019-2025
25 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $15.61 · 2021: $21.34 · 2022: $179 · 2023: $191 · 2024: $490 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $240.86 | 2019-2025 | Endosee, Ally II Ups, Paragard T 380a |
| Abbvie INC. | $183.21 | 2019-2023 | |
| Astellas Pharma US INC | $180.74 | 2023-2025 | Veozah |
| Duchesnay USA Incorporated | $83.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.19 | 2024-2025 | |
| Sage Therapeutics, LLC | $63.61 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $57.01 | 2025 | |
| Mayne Pharma Commercial LLC | $55.42 | 2024-2025 | |
| Pfizer INC. | $53.14 | 2023-2024 | |
| Organon LLC | $48.77 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $48.20 | 2019-2023 | Gardasil 9 |
| Hologic Sales and Service, LLC | $47.38 | 2024-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Smith+Nephew, INC. | $38.65 | 2024-2025 | Pico 14 |
| Mylan Pharmaceuticals INC. | $37.03 | 2022 | |
| Gynesonics, INC. | $31.59 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $31.40 | 2024-2025 | Slynd |
| Therapeuticsmd, INC. | $29.14 | 2019 | |
| Agile Therapeutics, INC. | $28.38 | 2022 | |
| Millicent US INC | $24.50 | 2025 | Femlyv |
| Sumitomo Pharma America, INC. | $22.46 | 2023 | Myfembree |
| Ascend Therapeutics US, LLC | $19.98 | 2022 | |
| Medtronic, INC. | $19.07 | 2023 | Truclear |
| Heron Therapeutics, INC. | $13.61 | 2023 | Zynrelef |
| Avion Pharmaceuticals | $12.87 | 2023 | Balcoltra |
| Meditrina | $8.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshelle Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.